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Dose finding study of granisetron in patients receiving high-dose cisplatin
chemotherapy
A. Riviere on behalf of The Granisetron Study Group
The Granisetron Study Group comprises: A. Riviere and J.F. Heron, Centre Francois Baclesse, Caen, France; B.N. Bui, Fondation
Bergonie, Bordeaux, France; H. Neumann, St JosefHospital, Bochum, Germany; D. Cupissol, Centre Val D'Aurelle II,
Montpellier, France; D. Kamanabrou, Fachklinik Hornheide, Muinster, Germany; A. Van de Merwe, Tygerberg Hospital,
University ofStellenbosh, Cape Town, South Africa; J.P. Jordaan, University ofNatal, Durban, South Africa; W. Meinerz,
Vincenz, Krankenhaus, Paderborn, Germany; L. Adenis, Centre Oscar-Lambret, Lille, France; L. Cals, H6pital Coste-Boyere, La
Garde, Toulon, France; B. Chevallier, Centre Henri Becquerel, Rouen, France; M. Schneider, Centre Antoine Lacassagne, Nice,
France; P. Federspil, HNO-Universitatsklinik, Homburg, Germany; P. Fumoleau, Centre Rene Gauducheau, Nantes, France; M.
Westerhausen, St Johannes-Hospital, Duisburg, Germany; P. Kerbrat, Centre Eugene Marquis, Rennes, France; H. Litschmann
Kreiskrankenhaus, Krumbach, Germany; C. Dott, SmithKline Beecham Pharmaceuticals, Reigate, Surrey, UK.
Summary The efficacy and safety of three different doses of granisetron (2pjgkg-', group A; 10;Lgkg-',
group B; 40jiygkg-', group C) were compared in a randomised, double-blind study of 157 patients due to
receive high-dose cisplatin therapy (mean dose >97 mg m-2). In each group, up to two 3 mg rescue doses of
granisetron were allowed if more than mild nausea or vomiting occurred. In group A 30.8%, in group B
61.5% and in group C 67.9% of patients were complete responders (i.e. no vomiting or nothing worse than
mild nausea) during the first 24 h. These differences are significant between groups A and B, and A and C.
There were no statistically significant differences in any efficacy variable between the 10 g kg-' and
40 jig kg- groups, although in each case the trend favoured the higher dose. Additional rescue doses resulted
in resolved or improved symptoms in 95.3% for the first rescue dose and 93.3% for the second. Over the 7
days of the study, 82.7%, 82.7% and 86.8% of patients in groups A, B and C respectively were treated with
granisetron alone. Headache was the most common side-effect, reported by 9.6% of patients; the majority of
headaches were mild. There was no difference between the treatment groups regarding the adverse event rate.
We concluded that prophylactic doses of 10 or 40 jig kg-' lead to a safe and satisfactory degree of control of
nausea and vomiting induced by high-dose cisplatin.
Nausea and vomiting are side-effects frequently associated
with many cytostatic chemotherapeutic agents and are a
major cause of distress to the patient (Coates et al., 1983).
Cisplatin is one of the most commonly used agents, especially
for treatment of testicular, ovarian, head and neck and lung
cancer. Cisplatin-induced emesis has been shown to have a
biphasic pattern with acute and delayed symptoms. Acute
emesis with cisplatin begins approximately 6 h after
chemotherapy administration and its severity is related to
gender and cisplatin dose. Delayed emesis is usually less
severe, related to incomplete control of acute emesis (Roila et
al., 1991), and occurs 24h to 5 days after chemotherapy
(Kris et al., 1985; Gralla et al., 1981).
There is now evidence that emesis control during chemo-
therapy acts on the quality and cost of treatment by allowing
a better compliance to scheduled drug doses. It improves
patient quality of life by reducing the intensity and the
number of side-effects and therefore reduces length of hos-
pitalisation and treatment costs (Laszlo & Lucas, 1981).
Antiemetic treatment should aim to provide total control
of emesis, particularly during the first cycle. With the best
conventional antiemetic treatment, such as a combination of
high-dose metoclopramide, corticosteroids and benzo-
diazepine, cisplatin-induced emesis can be controlled in up to
60% of patients (Kris, 1987). However, treatment is
associated with frequent side-effects, consisting of extra-
pyramidal reactions and sedation (Kris et al., 1983).
Research on the pathophysiology of chemotherapy-induced
vomiting has demonstrated the role of serotonin (5-hydroxy-
tryptamine). Serotonin is released by enterochromaffin cells
in the upper gastrointestinal tract, where it can act on specific
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receptors recognised as 5-HT3 (Borison & McCarthy, 1983).
Studies on the ferret have shown the efficacy of 5-HT3 recep-
tor antagonists against chemotherapy-induced vomiting
(Blower, 1990). Granisetron, a highly potent and selective
5-HT3 receptor antagonist, is very effective in protecting
against emesis induced by either high-dose cisplatin or
moderately emetogenic agents (Tabona, 1990).
In a placebo-controlled study of 28 patients receiving high-
dose cisplatin chemotherapy, granisetron was successful in
protecting 13/14 patients during the first 24 h (Cupissol et al.,
1990). When compared with a chlorpromazine-dexametha-
sone antiemetic regimen, in patients receiving moderately
emetogenic chemotherapy, a significantly greater number of
patients were controlled with granisetron (70% complete re-
sponders) compared with the control group (49% complete
responders; P = 0.0013) (Marty, 1990).
In patients receiving high-dose cisplatin chemotherapy,
granisetron was at least as effective as a metoclopramide plus
dexamethasone regimen with an approximately 70% com-
plete responder rate in both groups. No extrapyramidal side-
effects were observed in the r;anisetron group. The side-effect
rate was the same in the two groups, but in the granisetron
group events were less severe and easily resolved (Chevallier,
1990).
In these trials granisetron was administered as a 40jig kg-'
single dose, with the option of two additional doses of
40jigkg-' to be used as rescue for breakthrough symptoms.
This schedule has been compared with 160jig kg-' dosage in
patients receiving highly and moderately emetogenic
chemotherapy. In both cases there was no significant
difference between the two groups regarding emesis control
at 24 h, efficacy over a period of 7 days, time to first emetic
episode or the adverse event frequency (Soukop, 1990). The
present study was initiated in order to further investigate the
efficacy and safety of lower dosages of granisetron.
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Patients and methods
Study design
The aim of this study was to compare the efficacy and safety
of three different doses of granisetron in patients receiving
cisplatin therapy for the first time. Each patient was ran-
domly assigned in a double-blind fashion to receive a single
intravenous dose of 2, 10 or 40tg kg-' granisetron. The
study was conducted at 17 centres in three countries (France,
Germany and South Africa).
Patients
Eligible patients were inpatients due to receive cisplatin-
containing chemotherapy for the treatment of histologically
confirmed malignant disease and who had given their written
informed consent.
Chemotherapy was to be delivered on a single day and to
contain cisplatin at a minimum dosage of 75 mg m-2 given as
an infusion over a period of 3 h. Other cytostatic agents were
permitted after cisplatin, but only those that would not be
routinely covered by antiemetic therapy.
Patients were excluded from the study if they had marked
hepatic or renal dysfunction, cardiovascular disease, active
peptic ulcer, gastrointestinal tract obstruction or brain
tumour or had a history of chronic nausea or vomiting.
Patients were also excluded if they received corticosteroids. If
medications with a CNS effect were taken, their daily
regimen was not to be changed for the week before the study
day. The study was conducted according to the Declaration
of Helsinki and approval for the study was obtained from
local ethics committees.
Antiemetic therapy
Patients received granisetron as a single infusion over 5 min
to be completed 5 min before the start of cisplatin therapy. If
moderate or severe nausea or vomiting occurred, up to two
additional 3 mg granisetron infusions were allowed. These
two administrations could not be given within 10 min of one
another. If this treatment failed to maintain control of
emesis, patients were withdrawn from the study and treated
with conventional antiemetics of the physician's choice.
Efficacy assessments
Efficacy was measured by the patient, the clinician and by
recording the use of additional antiemetics. Patients were
asked about their subjective assessment of nausea and
vomiting. Nausea was recorded on a four-point scale as
either none, mild, moderate or severe, and episodes of
vomiting were recorded on a four-point scale as either no
vomiting, one episode of vomiting, 2-4 episodes of vomiting
or more than four episodes of vomiting. Patients' appetites
were also recorded and compared with their appetites in the
week before chemotherapy commenced. The evaluations were
done prior to the start of chemotherapy and thereafter at 6,
12, 18 and 24h.
The clinician's objective assessment of emetic control was
given at the end of the first 24 h of the study and rated as
very good, good, average, poor or very poor. The need for
additional granisetron or other anti-emetics was recorded,
including the reason (nausea or vomiting) and outcome
(resolved, improved or no improvement). During the follow-
ing 6 days, the use of any other antiemetics was
recorded.
Efficacy was defined according to the following
classification:
Complete response
Major response
No vomiting and nothing worse than
mild nausea over the 24 h after the start
of cytostatic chemotherapy.
One episode of vomiting and/or
moderate/severe nausea over the 24 h
Minor response
Failure
after the start of cytostatic
chemotherapy.
Two to four vomiting episodes (regard-
less of nausea) over the 24 h after the
start of cytostatic chemotherapy.
More than four emetic episodes (regard-
less of nausea) over the 24 h after the
start of cytostatic chemotherapy.
Clinical and laboratory monitoring
Objective clinical assessment of alertness and general well-
being was recorded before and at the start of therapy and
then at 6, 12, 18, 24 h after the start of cisplatin infusion.
Blood pressure, pulse rate and temperature were recorded at
the same time points and at the screening examination and at
the follow-up visit at 7 days. The usual haematological and
clinical chemistry laboratory analyses were performed on
blood and urine samples at the screening visit, on the treat-
ment day and at the follow-up visit.
Adverse events
Patients were asked directly at the screening visit, on the
treatment day and at the follow-up visit if they felt different
in any way since the start of the treatment and any adverse
events were recorded. Adverse events were also recorded by
spontaneous reports from patients and direct observation by
the staff.
For each event reported, the physician was required to give
duration, severity, outcome and treatment given, and to
assess the relationship to granisetron as unassessable,
unrelated, probably unrelated, probably related, related.
Adverse events were analysed for frequency. A serious
adverse event was defined as any event that was fatal, life-
threatening, disabling or incapacitating or resulted in hos-
pitalisation, prolonged a hospital stay, or was associated with
congenital abnormality, carcinoma or overdose. Serious
adverse affects were studied separately.
Statistical analysis
The target size for each treament group was 60 patients,
giving a power of at least 80% to detect a difference of 26%
in the percentage of complete response between any pair of
dose groups. An interim analysis was planned to be per-
formed on the results of the first 60 patients to allow any
ineffective dose to be dropped from the study.
A chi-square test was used to test for differences between
the three treatment groups for proportion of adverse events,
complete responses and good/very good global efficacy
assessments. A Cox log-rank test was used to test for
differences between the three treatment groups for time to
first nausea, first moderate/severe nausea, first vomiting or
retching, less than complete response, use of granisetron
rescue medication and use of conventional antiemetic
medication.
A two-tailed significance level of 4.8% was used to test
whether the result is significant for the chi-square test on
complete response, as this was tested in the interim analysis.
In all other cases a two-sided significance level of 5% was
used to determine whether the event was to be regarded as
significant.
If there was sufficient evidence to suggest a significant
difference between the three treatment groups, three pairwise
comparisons were made between the 2 and 10lg kg-', 2 and
40tg kg-' and 10 and 40 sgkg-' groups. To maintain the
two-tailed significance level of 5%, the Bonferroni correction
was used. That is, for each pairwise comparison a two-tailed
significance level of 1.600% for complete response and
1.667% for all other items was used to determine if the result
was to be regarded as statistically significant. All patients
were included in the efficacy and safety analysis.GRANISETRON IN HIGH-DOSE CISPLATIN 969
Results
Demography
One hundred and fifty-seven patients were enrolled into this
trial. Fifty-two patients received granisetron at a dose of
2 lgkg-, 52 at a dose of l0figkg-I and 53 at a dose of
40 jgkg-'. Demographic data are given in Table I. There
were 87 male and 70 female patients, with a greater propor-
tion of males in the 2fig kg-' group than in the 40 jig kg-'
group. Age and alcohol usage were well balanced between
the three groups. The main primary disease sites were head
and neck (37 patients), ovary (24 patients), lung (21 patients)
and cervix (18 patients) (Table II), and were fairly evenly
distributed between the three groups.
All patients received cisplatin-containing chemotherapy.
The mean dose of cisplatin was 95.9 mgm-2 in the 2fig kg-'
granisetron group (range 60-150 mg m-2), 96.2 mg m-2 in
the 10jg kg' granisetron group (range 75-120 mgmi-2) and
99.3 mg m-2 in the 40jig kg-' granisetron group (range
75-200 mgm-2). One patient in the 2jig kg-' group in fact
received 60 mg m-2 cisplatin in violation of the protocol.
Efficacy during thefirst 24 h
The efficacy in the first 24 h is presented in Table III. At the
end of the first 24 h, 30.8% of patients in the 2jigkg-'
granisetron group (group A), 61.5% in the 10 igkg-'
granisetron group (group B) and 67.9% in the 40,igkg-'
granisetron group (group C) were complete responders. In
total, three patients were classified as complete responders
who received additional doses of granisetron in the first 24 h
(two in the 10iLgkg-' group and one in the 40jgkg'
group).
Table I Demographic data
Granisetron dose
2jigkg-' 10jigkg-' 40jAg kg-
Males 33 28 26
Females 19 24 27
Mean age (years) 57.8 51.0 54.8
Age range (years) 28-79 17-79 23-74
Mean height (cm) 166.4 165.4 167.2
Mean weight (kg) 66.6 63.7 66.2
No alcohol consumption 22 24 22
Table II Primary disease site
Granisetron dose
2jgkg-' 10jLgkg- 40jigkg-]
Head and neck 10 17 10
Ovary 7 9 8
Lung 9 5 7
Cervix 3 7 8
Urethra bladder 3 2 5
Melanoma 4 3 2
Oesophagus 4 2 1
Breast 1 1 4
Others (13 sites) 11 6 8
Total 52 52 53
Table III Twenty-four hour efficacy
Granisetron dose
2jigkg- I 10jLgkg-] 40jlgkg-'
(n = 52) (n = 52) (n = 53)
Complete response 16 (30.8%) 32 (61.5%)a 36 (67.9%)a
Major response 12 (23.1%) 8 (15.4%) 9 (17.0%)
Minor response 17 (32.7%) 9 (17.3%) 5 (9.4%)
Failure 7 (13.5%) 3 (5.8%) 3 (5.7%)
No nausea 23 (44.2%) 31 (59.6%) 35 (66.0%)
No vomiting 20 (38.5%) 34 (65.4%) 39 (73.6%)
aP<0.001 for 2 vs 10igkg-' and 2 vs 40jIgkg-'.
There were significant differences between these three
groups regarding the proportion of complete responders.
Using the Bonferroni correction, a significant difference was
found between groups A and B (P=0.002) and between
groups A and C (P = 0.001) but not between groups B and
C. Moreover, 28 patients (53.8%), 40 patients (76.9%) and
45 patients (84.9%) in the respective groups experienced no
more than one episode of vomiting or retching.
The same results (significant differences between A and C
and between A and B) were observed when analysing time to
less than a complete response and time to the first vomiting.
For all cases first events tended to occur earlier in the
2 jg kg- I dose group. With respect to time or first moderate/
severe nausea, there was a significant difference between
group A and C but not between A and B or between B and
C.
Thirty-two patients (61.5%) from group A, 22 patients
(42.3%) from group B and 17 patients (32.1%) from group C
received a rescue medication (granisetron or other agents)
during the first 24 h. The use of any rescue medication and
time to rescue were significantly different between groups A
and B (P = 0.002) and between groups A and C (P<0.001)
when using the Bonferroni correction. Details about addi-
tional granisetron use are given in Table IV. Thirty patients
in group A, 19 in group B and 15 in group C received one
additional dose of granisetron. This resulted in resolution of
emesis in 86.7%, 63.1% and 60.0% of cases respectively. A
second additional dose was given to 40%, 57.9% and 46.7%
of patients in groups A, B and C and produced resolution of
symptoms in 41.6%, 81.8% and 28.6% of patients respec-
tively (Table V).
The clinician's global assessment of efficacy was good or
very good in 63.5%, 76.9% and 86.5% of cases. Using the
Bonferroni correction, a significant difference was found
between groups A and C (P = 0.007) but not between groups
A and B or between groups B and C. Only two patients in
the 2jig kg-' granisetron group and one patient in the
40jg kg-' group were withdrawn from the trial for lack of
antiemetic efficacy. The clinician had assessed the patient's
well-being as 'well' in most of the cases with no major
difference between the three treatment groups.
Efficacy over 7 days
Nine patients (17.3%) from group A, nine patients (17.3%)
from group B and seven patients (13.2%) from group C
Table IV Summary of additional granisetron use
Granisetron dose
2jigkg-] 10 igkg-' 40jigkg-'
(n =52) (n = 52) (n =53)
Rescue therapy, no. of
additional doses
0 22 (42.3%) 33 (63.5%) 38 (71.7%)
1 30 (57.7%) 19 (36.5%) 15 (28.3%)
2 12 (23.1%) 11 (21.1%) 7 (13.2%)
3 1 (1.9%)
4 1 (1.9%)
Table V Effect of additional granisetron doses
Granisetron dose
2jigkg-' 10jigkg- 40jigkg-]
(n =52) (n = 52) (n = 53)
Rescue therapy, no. of
additional doses
Resolved 26 12 9
Improved 3 5 6
Failure 1 2 0
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Table VI Adverse events occurring in more than 5% of patients
Granisetron dose
2 tLgkg-] 10 lgkg- 40 Lgkg-
Headache 6 (11.5%) 4 (7.7%) 5 (9.4%)
Anaemia .3 (5.8%) 1 (1.9%) 0
Hypertension 3 (5.8%) 2 (3.8%) 3 (5.7%)
Constipation 3 (5.8%) 2 (3.8%) 0
Diarrhoea 2 (3.8%) 3 (5.8%) 3 (5.7%)
needed other rescue medication. Thus, 82.7%, 82.7% and
86.8% respectively were treated with granisetron alone over
the 7 day study period. Using the Bonferroni correction, time
to first use of any additional antiemetic therapy during this
period was significantly different between groups A and B
(P = 0.005) and between groups A and C (P<0.001), but not
between groups B and C.
Clinical monitoring and laboratory tests
Double-flagged change in vital signs occurred for 13 patients
(four, four and five patients in groups A, B and C respec-
tively). No case was considered as study drug related by the
clinician. No major changes were seen in laboratory results
between predose and follow-up time.
Adverse events
The adverse event incidence and most frequent adverse
events reported are presented in Table VI. Headache was the
most commonly reported event, and the incidence of this or
any other event did not appear to be related to the ran-
domised prophylactic dose of granisetron. Headache was
considered as mild and responded to corrective therapy
except in one patient who rated headache as severe, however
this was present before the start of granisetron therapy.
Severe or serious adverse events were reported for four
patients in group A, six patients in group B and one patient
in group C. All but one were considered by the investigator
to be unrelated to the study drug (see below). Two patients
died. In one case, the cause of death (acute hepatopathy) was
considered by an independent expert to be related to
halothane compounds given prior to granisetron as general
anaesthesia for an endoscopy. The second patient who died
during the study period developed severe aplasia. The
clinician considered the death to be related to toxic shock,
septicaemia and chemotherapy toxicity. No relationship was
found in this study between adverse event rate and
administered dose of granisetron.
Discussion
Cisplatin chemotherapy is associated with vomiting in 93%
of patients when given at more than 80 mg m-2 (Gralla et al.,
1981; Cuppisol, 1990). Nausea and vomiting are considered
as separate phenomena, and nausea can occur in the absence
of vomiting. In a French crossover trial which studied
antiemetic treatment, it was noted that the patients'
preference criteria were more closely related with the effect of
antiemetics on nausea, while for the physicians judgement
was based on vomiting or retching (Bonneterre et al., 1991).
In the paper presented here, complete response includes an
assessment of both vomiting (absent) and nausea (no more
than mild), and this seems to be very important as far as
patients' quality of life is concerned.
Use of a single dose ofgranisetron as antiemetic treatment,
resulted in, respectively, 30.8%, 61.5% and 67.9% complete
response rates for the 2, 10 and 40jg kg-' groups. In the
same groups 42.3%, 65.4% and 71.7% of patients respec-
tively did not receive any additional granisetron. There was a
significant difference between the 2pg kg-' group and the
other two groups. Although results were numerically better
in the 401tg kg-' group, there was no significant difference
between the 10 and 401Igkg-1 groups. When nausea and
vomiting were examined as independent variables it can be
seen that 40 gg kg-' was better at controlling both these
symptoms compared with lower doses and the difference was
greater than when complete response was presented.
These results in the 40ytgkg-' group are similar to those
obtained in other granisetron studies. In high-dose cisplatin
studies, granisetron given as a single dose of 40fig kg-' gives
complete response rates of between 55% and 75% (Cheval-
lier, 1990; Soukop, 1990). This response rate does not seem
to be improved significantly by increasing the dose of
granisetron to 160fig kg-' (Soukop, 1990). In a Canadian
double-blind trial in which 149 patients were enrolled,
granisetron was administered as an 80 ,g kg-' single dose
and compared with a high-dose metoclopramide-dexametha-
sone-diphenhydramine combination. In both groups 46% of
the patients were free of vomiting for 24 h. This similarity to
metoclopramide-dexamethasone was also seen at 401tg kg-'
(Chevallier, 1990), which demonstrates that prophylactic
doses greater than 40tig kg-' are not more efficacious.
In this study, granisetron was effective when used as rescue
therapy. After the first emetic episode (nausea or vomiting
95.3% ofpatients and after the second event 93.3% had their
symptoms resolved or improved. There was evidence to sug-
gest a difference in the three treatment groups regarding the
first use of additional granisetron therapy (P<0.001). No
significant difference was found between the three groups
regarding additional granisetron efficacy.
Treatment was well tolerated. In no case was granisetron
associated with severe adverse events. The usual granisetron-
related side-effects such as headache and constipation were as
frequent as in other studies (Chevallier, 1990; Marty, 1990;
Smith, 1990; Soukop, 1990; Venner, 1990) and there was no
relationship between granisetron doses and adverse event
rate.
Conclusion
In this study, prophylactic doses of 10 or 40iLg kg-' graniset-
ron given intravenously were clinically and statistically more
effective than a dose of 2 gig kg-' in preventing cisplatin-
induced enesis. It can be concluded that at the two higher
dose levels, granisetron leads to a safe and satisfactory degree
of control of nausea and vomiting induced by high-dose
cisplatin.
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